NIKKEI 225
39,173.15 +368.50 (+0.95%) HANG SENG
18,028.01 +0.30 (+0.00%) CRUDE OIL
81.61 -0.02 (-0.02%) GOLD FUTURES
2,336.60 -7.80 (-0.33%) DOW
39,411.21 +260.91 (+0.67%) Bitcoin GBP
48,129.09 -980.17 (-2.00%)
ZVRA Jun 2024 5.000 call
| Previous close | 0.0500 |
| Open | 0.0300 |
| Bid | 0.0000 |
| Ask | 0.3500 |
| Strike | 5.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0200 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 544 |
Simply Wall St.Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
We feel now is a pretty good time to analyse Zevra Therapeutics, Inc.'s ( NASDAQ:ZVRA ) business as it appears the...
GlobeNewswireZevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA® is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders (UCDs) involving deficienc
- GlobeNewswire
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on pharmacokinetics of morning and nighttime doses of KP1077 European Commission has granted Orphan Drug Designation for KP1077 for the treatment of idiopathic hypersomnia CELEBRATION, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics
